Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra in CINCA/Muckle-Wells syndrome and systemic juvenile idiopathic arthritis
2005-004008-36Phase 2Completed
- Sponsor
- Istituto Giannina Gaslini
- Start
- Jan 2012
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of anakinra in neonatal-onset multisystem inflammatory disease (NOMID), Muckle-Wells syndrome (MWS) and systemic juvenile idiopathic arthritis (SJIA) (2 arms), sponsored by Istituto Giannina Gaslini. Primary endpoints: Responder rate in CINCA/Muckle-Wells syndrome, Responder rate in systemic juvenile idiopathic arthritis and 1 more. Started Jan 2012; status: completed.
02
Drugs
anakinra
03
Conditions
neonatal-onset multisystem inflammatory disease (NOMID)Muckle-Wells syndrome (MWS)systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on 2005-004008-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004008-36.